A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Status:
Completed
Trial end date:
2016-08-31
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, regimen-controlled, phase II, multicenter study will assess
the efficacy and safety of two different vismodegib regimens in participants with multiple
basal cell carcinoma. Participants will receive vismodegib 150 mg orally once daily either in
an intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo (Arm A) or as 24
weeks induction followed by an intermittent schedule of 8 weeks placebo followed by 8 weeks
vismodegib (Arm B). Anticipated time on study treatment is 72 weeks.